Todos os estudos
RecrutamentoFASE2INTERVENCIONISTA

A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

This research study is testing a new daily medicine, etavopivat, for children and teenagers with sickle cell disease. We want to understand how safe it is and how it works in the body. We'll also be looking to see if it has any benefits for those taking it. Participants will take the medicine for 96 weeks, which is about 1 year and 10 months. During this time, they will have regular check-ups. The study aims to gather important information to help us understand if etavopivat could be a new treatment option for sickle cell disease.

Em resumo

Status
Recrutamento
Fase
FASE2
Patrocinador
Forma Therapeutics, Inc.
Meta de inscrição
95
Iniciar
12 de janeiro de 2023
Conclusão estimada
08 Aug 2029

Sobre o que é este estudo?

Sickle cell disease is a lifelong condition that affects red blood cells. These cells, which are usually round and flexible, become stiff and C-shaped, like a sickle. This can block blood flow, causing pain, tiredness, and other serious health problems. It's a condition that can have a big impact on daily life, especially for young people.

This study, called "A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease," is looking at a new medicine called etavopivat. This medicine is designed to be taken once a day by mouth. The main goal is to understand if etavopivat is safe for children and teenagers with sickle cell disease and how their bodies handle the medicine, including how long it stays in their system.

Doctors are also interested in finding out if taking etavopivat can offer any improvements for people with sickle cell disease. By carefully studying this medicine, researchers hope to learn if it could become a helpful new treatment in the future. This is a "Phase 2" study, which means it's one of the earlier stages of testing a new medicine in people.

Pontos principais

  • This study is for children and teenagers with sickle cell disease.
  • It's testing a new daily medicine called etavopivat.
  • The main goals are to check the medicine's safety and how it works in the body.
  • Participation involves taking medicine daily for about 1 year and 10 months, with regular check-ups.
  • The study aims to see if etavopivat could be a new treatment option for sickle cell disease in the future.

Quem pode ser elegível?

This study is looking for children and teenagers with sickle cell disease. Participants must be between 6 months and 18 years old when they join the study. If you're under 18, your parent or guardian will need to give their permission for you to take part, and you'll also need to agree if you're old enough.

To be considered, you need to have a confirmed diagnosis of sickle cell disease, which can be shown by previous blood tests. Your haemoglobin level (a measure of red blood cells) also needs to be within a certain range. The study is specifically for those with more severe sickle cell disease, meaning you've had certain health issues related to your condition in the past year, such as several pain crises or hospital stays. Your doctor will be able to check all these details to see if you might be a good fit.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Are you between 6 months and 18 years old?
  2. Do you have a diagnosis of sickle cell disease?
  3. Has your sickle cell disease caused you to have certain serious health problems in the past year (like several pain crises or hospital stays)?
  4. Is your haemoglobin level within the required range (between 5.5 and 10.5 g/dL)?
  5. Are your parents or guardians willing to give permission for you to join?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, you'll be taking the study medicine, etavopivat, once a day by mouth for 96 weeks (that's about 1 year and 10 months). During this time, you'll have regular visits to the clinic so the study team can check on your health and how you're responding to the medicine. These visits will likely include physical exams, blood tests, and discussions about how you're feeling. After the 96-week treatment period, there will be one final check-up about a month later to make sure everything is okay.

Riscos e benefícios potenciais

Taking part in any medical study has potential benefits and risks. A possible benefit of this study is that etavopivat might help improve your sickle cell disease. However, it's also possible that the medicine may not help, or it might cause side effects. The study team will carefully monitor your health throughout the study to identify any problems as quickly as possible. You are free to leave the study at any time, for any reason, without it affecting your usual medical care.

Localizações (18)

  • The Hospital for Sick Children
    Código postal verificado
    Toronto, Canadá· Concluído
  • HCL-HOPITAL LYON SUD_Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe)
    Código postal verificado
    Lyon, França· Ainda não recrutando
  • APHP - Centre de Référence des Syndromes
    Código postal verificado
    Paris, França· Ainda não recrutando
  • Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle
    Não verificado
    Roeun, France· Ainda não recrutando
  • KEMRI CRDR Siaya Clinical Research Annex, Country Referral Hospital
    Código postal verificado
    Siaya, Kenya· Recrutamento
  • KEMRI-Walter-Reed Kericho
    Código postal verificado
    Kericho, Kenya· Recrutamento
  • Kombewa Clinical Research Centre
    Código postal verificado
    Kisumu, Kenya· Recrutamento
  • Ahero Clinical Trials Unit
    Código postal verificado
    Kisumu, Kenya· Recrutamento
  • American University of Beirut Medical center
    Código postal verificado
    Beirut, Lebanon· Recrutamento
  • Hospital Nini
    Código postal verificado
    Tripoli, Lebanon· Recrutamento
  • University of Nigeria Teaching Hospital (UNTH)
    Não verificado
    Ituku-Ozalla, Nigeria· Recrutamento
  • Lagos University Teaching Hospital, Lagos
    Código postal verificado
    Lagos, Nigeria· Recrutamento

Perguntas frequentes

O que é a doença falciforme?

Sickle cell disease is a genetic condition where red blood cells become stiff and C-shaped, which can block blood flow and cause pain and other health problems.

What is etavopivat?

Etavopivat is a new medicine being tested in this study. It's a tablet taken once a day by mouth for people with sickle cell disease.

Quanto tempo dura o estudo?

If you join, you will be taking the medicine for 96 weeks (about 1 year and 10 months), followed by a final check-up about 4 weeks later.

Who can take part in this study?

The study is for children and teenagers with confirmed sickle cell disease, aged between 6 months and 18 years, who meet specific health criteria.

What do they hope to learn from this study?

Researchers want to learn if etavopivat is safe, how it works in the body, and if it can help improve the health of people with sickle cell disease.

Como saber mais

Novo Nordisk

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study to Evaluate the Pharmacokinetics and Safety of Etavo…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.